Dermata Therapeutics (DRMA) Stock: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$1.19
-0.01 (-0.83%)
▼
5d:
-3.25%
30d:
-13.77%
90d:
-2.46%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DRMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DRMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $1.19, which is considered slightly low relative to its 30-day fair value range of $1.14 to $1.50.
Technical Outlook: Technically, DRMA is showing sideways momentum. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+236.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DRMA is showing sideways momentum. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+236.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.14 -
$1.50
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 236.1% below Wall St target ($4.00)
- NEUTRAL: Bottoming setup forming (56/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.14 -
$1.50
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.58
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.83
Wall Street Target
$4.00
(+236.1%)
Share & Embed Analysis
Last updated: September 11, 2026 11:33 PM ET
Data refreshes hourly during market hours. Next update: 12:33 AM
Data refreshes hourly during market hours. Next update: 12:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
